Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure
- PMID: 32232914
- DOI: 10.1002/ejhf.1789
Prevalence of risk of thrombosis and of bleeding and antithrombotic treatment in patients with heart failure
References
-
- Witt BJ, Gami AS, Ballman KV, Brown RD, Meverden RA, Jacobson SJ, Roger VL. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J Card Fail 2007;13:489-496.
-
- Massie BM, Collins JF, Ammon SE, Armstrong PW, Cleland JG, Ezekowitz M, Jafri SM, Krol WF, O'Connor CM, Schulman KA, Teo K, Warren SR; WATCH Trial Investigators. Randomized trial of warfarin, aspirin and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation 2009;119:1616-1624.
-
- Maggioni AP, Anker SD, Dahlstrom U, Filippatos G, Ponikowski P, Zannad F, Amir O, Chioncel O, Crespo Leiro M, Drozdz J, Erglis A, Fazlibegovic E, Fonseca C, Fruhwald F, Gatzov P, Goncalvesova E, Hassanein M, Hradec J, Kavoliuniene A, Lainscak M, Logeart D, Merkely B, Metra M, Persson H, Seferovic P, Temizhan A, Tousoulis D, Tavazzi L; Heart Failure Association of the ESC (HFA). Are hospitalized or ambulatory patients with heart failure treated in accordance with European Society of Cardiology guidelines? Evidence from 12440 patients of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail 2013;15:1173-1184.
-
- Melgaard L, Gorst-Rsmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc score in predicting ischemic stroke, thromboembolism, and death in patients with heart failure with and without atrial fibrillation. JAMA 2015;314:1030-1038.
-
- Lane DA, Lip GY. Use of the CHA2DS2-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvascular atrial fibrillation. Circulation 2012;126:860-865.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
